Welcome

The Post-Finasteride Syndrome Foundation’s primary mission is to facilitate research on the characterization, underlying biologic mechanisms and treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS and providing support for patients suffering from the condition.

Read our FDA Citizen Petition to remove finasteride from the market.

Adverse drug reaction reports worldwide

PFS research studies published

Known suicides worldwide

Doctors & researchers speaking out

Nations warning of PFS

National media reports worldwide

Sources

Patient Services

Connect with other PFS patients

Consult knowledgeable doctors

Report your side effects

Read the latest research

Data Available on Adverse Side Effects of 5α-RIs Don’t Conclusively Suggest They’re Safe, Say Researchers at Boston University School of Medicine

SOMERSET, N.J., Sept. 7, 2015 – Data from preclinical and clinical studies have provided substantial evidence that 5α-Reductase inhibitors (5α-RIs) such as finasteride and dutasteride cause loss or reduction of libido, increase the risk of erectile dysfunction and ejaculatory dysfunction, and may contribute to the onset of depression. These agents interfere with the biosynthesis and […]

Suggestion That Sexual Side Effects Appear Early in Finasteride Therapy then Return to Normal is ‘Inaccurate,’ Say Researchers at Boston University School of Medicine

SOMERSET, N.J., Aug. 26, 2015 – Twenty-five percent of men currently taking finasteride or dutasteride (brand names Proscar and Avodart) for the treatment of benign prostate enlargement (BPH), appear not to benefit from taking these medications. Those prescribed Propecia or Avodart for male pattern hair loss are also at risk for adverse events elicited by […]

2015 PFS Foundation Annual Address

Aug. 4, 2015 Dear Friends: By many accounts, we’ve reached a tipping point on post-finasteride syndrome awareness within the medical community. The most significant advancement occurred in March, when the U.S. National Institutes of Health added PFS to its Genetic and Rare Diseases Information Center. “Studies are under way to understand the safety profile of […]

Southwest Brain Bank Launches PFS Brain and Spinal Cord Donation Program

SOMERSET, N.J., July 15, 2015 – The Southwest Brain Bank (SWBB) in the Department of Psychiatry at the University of Texas Health Science Center in San Antonio has received its first donation of the brain and spinal cord of a post-finasteride syndrome (PFS) patient and formed a program to collect and study post-mortem human brain […]

Doctors & Researchers Speaking Out

Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.

An important pattern of symptoms was common among all cases who committed suicide in the setting of finasteride use – insomnia and persistent sexual dysfunction after medication discontinuation. Insomnia and fatigue/tiredness were some of the most debilitating symptoms… Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.

Finasteride and Suicide: A Postmarketing Case Series: Dermatology, January 14, 2020

Michael S. Irwig, MD, Attending Endocrinologist
Beth Israel Deaconess Medical Center

Health care professionals should…conduct a full evaluation and a…risk-benefit assessment for patients before each prescription of finasteride.

As prescribers, our primary duty is to do no harm. Health care professionals should keep themselves abreast of these potential signals and, accordingly, conduct a full evaluation and a detailed, personalized risk-benefit assessment for patients before each prescription of finasteride.

Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia: JAMA Dermatology, November 2020

Roger S. Ho, MD, Associate Professor of Dermatology
NYU Langone Health

Two subjects—eight percent—committed suicide during or after the study.

While the sexual side effects of 5ARIs are well known, there may be persistent genitourinary, physical, psycho-cognitive, anti-androgenic and penile vascular changes after 5ARI discontinuation. Use of 5ARIs for treatment of AGA may lead to persistent sexual, genitourinary, physical, psycho-cognitive, and anti-androgenic sequelae even after cessation of 5ARI therapy… Two subjects (8%) committed suicide during or after the study.

Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia: Translational Andrology and Urology, April 2020

Mohit Khera, MD, Director, Laboratory for Andrology Research
Baylor College of Medicine

FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks.

Finasteride inhibits Type II 5(alpha)-reductase, which metabolizes testosterone to the potent androgen 5(alpha)-dihydrotestosterone. FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks regarding growth, development and sexual function.

FDA response to Merck & Co.’s citizen petition requesting that finasteride be added to the List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population: May 2000

Janet Woodcock, MD, Director of the Center for Drug Evaluation and Research
US Food and Drug Administration